Please login to the form below

Not currently logged in
Email:
Password:

Therachon appoints new chief medical officer

Dr Maarten Kraan joins the company from AstraZeneca

Dr Maarten KraanBasel, Switzerland-based biotech company Therachon has appointed Dr Maarten Kraan as its new chief medical officer in a role that will see him focus on the clinical development of TA-46 - Therachon’s leading drug in development for achondroplasia.

Kraan has held numerous roles such as vice president, immunosciences at Bristol-Myers Squibb, vice president, head of clinical research and experimental development at Roche, and most recently as head of innovative medicines respiratory and inflammation at AstraZeneca.

Luca Santarelli, chief medical officer at Therachon, said: “Dr Kraan’s wealth of translational and drug development expertise is critical during this exciting time in our company’s growth. He will play a key role in guiding TA-46 from discovery into clinical development and helping us fulfill our mission of developing medicines for rare, genetic diseases.”

In addition to his new role Dr Kraan will continue to serve as an adjunct professor at Goteborg University in Sweden.

27th March 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics